Latest News and Press Releases
Want to stay updated on the latest news?
-
SCYNEXIS received a one-time non-refundable payment in Q4 2025 totalling $24.8 million from GSK SCYNEXIS announced dosing of the first patient using the intravenous (IV) formulation of SCY-247 in a...
-
The approval was granted based on additional topline positive safety results reinforcing favorable profile of CMND-100 in ongoing Phase I/IIa clinical trial Vancouver, Canada, March 04, 2026 (GLOBE...
-
HMG’s March 5 Phoenix Summit gathers C‑level tech leaders to explore AI, disruption, and iconic leadership. Two days left to register—don’t miss it.
-
Transformational Leader Bryan Ganz to Retire as CEO Conn Davis Appointed as Successor TJ Kennedy Appointed Chair of the Board ANDOVER, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Byrna...
-
The case alleges that NuScale failed to disclose that it entrusted its NPM commercialization to an entity that lacked significant prior experience.
-
VANCOUVER, British Columbia, March 02, 2026 (GLOBE NEWSWIRE) -- Westhaven Gold Corp. (TSX-V: WHN) (OTCQB: WTHVF) (“Westhaven” or the “Company”) announces the appointments of Allison Rippin Armstrong...
-
SAN DIEGO, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced highlights from the fourth and final day of Symposium 2026. Day 4 featured updates from some of the...
-
LOS ANGELES, Feb. 26, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises NuScale Power Corporation, (“NuScale” or the "Company") (NYSE: SMR) investors off a class action on behalf of investors...
-
HMG Strategy’s 2026 Phoenix Summit unites C-level tech leaders to explore AI, disruption, and iconic leadership shaping the enterprise of 2030
-
KT-621 (STAT6) BROADEN2 Phase 2b trial in atopic dermatitis (AD) ongoing, with data expected by mid-2027 KT-621 BREADTH Phase 2b trial in asthma ongoing, with data expected in late-2027 Initiated...